Literature DB >> 33499102

Does Vancomycin Resistance Increase Mortality? Clinical Outcomes and Predictive Factors for Mortality in Patients with Enterococcus faecium Infections.

Jatapat Hemapanpairoa1,2, Dhitiwat Changpradub3, Sudaluck Thunyaharn4, Wichai Santimaleeworagun2,5.   

Abstract

The prevalence of enterococcal infection, especially E. faecium, is increasing, and the issue of the impact of vancomycin resistance on clinical outcomes is controversial. This study aimed to investigate the clinical outcomes of infection caused by E. faecium and determine the risk factors associated with mortality. This retrospective study was performed at the Phramongkutklao Hospital during the period from 2014 to 2018. One hundred and forty-five patients with E. faecium infections were enrolled. The 30-day and 90-day mortality rates of patients infected with vancomycin resistant (VR)-E. faecium vs. vancomycin susceptible (VS)-E. faecium were 57.7% vs. 38.7% and 69.2% vs. 47.1%, respectively. The median length of hospitalization was significantly longer in patients with VR-E. faecium infection. In logistic regression analysis, VR-E. faecium, Sequential Organ Failure Assessment (SOFA) scores, and bone and joint infections were significant risk factors associated with both 30-day and 90-day mortality. Moreover, Cox proportional hazards model showed that VR-E. faecium infection (HR 1.91; 95%CI 1.09-3.37), SOFA scores of 6-9 points (HR 2.69; 95%CI 1.15-6.29), SOFA scores ≥ 10 points (HR 3.71; 95%CI 1.70-8.13), and bone and joint infections (HR 0.08; 95%CI 0.01-0.62) were significant risk factors for mortality. In conclusion, the present study confirmed the impact of VR-E. faecium infection on mortality and hospitalization duration. Thus, the appropriate antibiotic regimen for VR-E. faecium infection, especially for severely ill patients, is an effective strategy for improving treatment outcomes.

Entities:  

Keywords:  Enterococci; VRE; glycopeptide; risk factor; survival

Year:  2021        PMID: 33499102      PMCID: PMC7911214          DOI: 10.3390/antibiotics10020105

Source DB:  PubMed          Journal:  Antibiotics (Basel)        ISSN: 2079-6382


  32 in total

1.  Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis.

Authors:  Carlos A DiazGranados; Shanta M Zimmer; Mitchel Klein; John A Jernigan
Journal:  Clin Infect Dis       Date:  2005-06-28       Impact factor: 9.079

2.  Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia.

Authors:  Jung-Jr Ye; Shian-Sen Shie; Chun-Wen Cheng; Jeng-How Yang; Po-Yen Huang; Ting-Shu Wu; Ming-Hsun Lee; Ching-Tai Huang
Journal:  J Microbiol Immunol Infect       Date:  2017-10-05       Impact factor: 4.399

3.  Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality.

Authors:  E Lautenbach; W B Bilker; P J Brennan
Journal:  Infect Control Hosp Epidemiol       Date:  1999-05       Impact factor: 3.254

4.  Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: a matched control study.

Authors:  Michelle Gearhart; Jill Martin; Steve Rudich; Mark Thomas; Dave Wetzel; Joseph Solomkin; Michael J Hanaway; Jaime Aranda-Michel; Fred Weber; Leslie Trumball; Maryetta Bass; Ed Zavala; E Steve Woodle; Joseph F Buell
Journal:  Clin Transplant       Date:  2005-12       Impact factor: 2.863

5.  Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia.

Authors:  Kayoko Hayakawa; Dror Marchaim; Emily T Martin; Namita Tiwari; Adnan Yousuf; Bharath Sunkara; Harish Pulluru; Harikrishna Kotra; Asma Hasan; Suchitha Bheemreddy; Puja Sheth; Dae-Won Lee; Srinivasa Kamatam; Pradeep Bathina; Priyanka Nanjireddy; Indu K Chalana; Satyam Patel; Sarwan Kumar; Amit Vahia; Kimberly Ku; Victoria Yee; Jessie Swan; Jason M Pogue; Paul R Lephart; Michael J Rybak; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

6.  Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Authors:  Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-27       Impact factor: 3.254

7.  Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort.

Authors:  Anne M Butler; Margaret A Olsen; Liana R Merz; Rebecca M Guth; Keith F Woeltje; Bernard C Camins; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2010-01       Impact factor: 3.254

8.  Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan.

Authors:  Chien-Hsuan Chou; Nan-Yao Lee; Hsin-Chun Lee; Chia-Ming Chang; Ching-Chi Lee; Wen-Chien Ko
Journal:  J Microbiol Immunol Infect       Date:  2012-05-10       Impact factor: 4.399

Review 9.  Emergence of vancomycin-resistant enterococci.

Authors:  L B Rice
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

10.  Does vancomycin resistance increase mortality in Enterococcus faecium bacteraemia after orthotopic liver transplantation? A retrospective study.

Authors:  S Dubler; M Lenz; S Zimmermann; D C Richter; K H Weiss; A Mehrabi; M Mieth; T Bruckner; M A Weigand; T Brenner; A Heininger
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-31       Impact factor: 4.887

View more
  1 in total

1.  Polymicrobial periprosthetic joint infection and osteomyelitis of the tibia with circumferential abscess and skin ulcer 11 years after total knee arthroplasty.

Authors:  Yasuo Kunugiza; Takehiro Tanaka; Ryuichiro Hirota; Shigeki Kakunaga; Yasunori Okamoto; Shigeyoshi Tsuji
Journal:  Radiol Case Rep       Date:  2022-08-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.